Phase I clinical evaluation of bryostatin 1 in combination With 2-CdA [cladribine] in patients wth relapsed CLL [chronic lymphocytic leukaemia]

Trial Profile

Phase I clinical evaluation of bryostatin 1 in combination With 2-CdA [cladribine] in patients wth relapsed CLL [chronic lymphocytic leukaemia]

Completed
Phase of Trial: Phase I

Latest Information Update: 13 Jul 2006

At a glance

  • Drugs Cladribine (Primary) ; Bryostatin-1
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top